New Ray Medicine International Holding Limited revised earnings guidance for the fiscal year 2022. For the year, Board estimated that the Group's expected loss for Fiscal Year 2022 may be increased to approximately HKD 77.9 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.054 HKD | -8.47% | +35.00% | +8.00% |
03-25 | New Ray Medicine International Holding Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-18 | New Ray Medicine International Forecasts Decline in 2023 Loss | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.00% | 11.56M | |
-29.72% | 15.83B | |
-22.89% | 12.31B | |
-24.53% | 6.59B | |
+15.23% | 6.45B | |
-12.43% | 5.94B | |
-1.90% | 4.66B | |
+62.00% | 4.59B | |
-5.94% | 3.96B | |
-9.36% | 3.55B |
- Stock Market
- Equities
- 6108 Stock
- News New Ray Medicine International Holding Limited
- New Ray Medicine International Holding Limited Revises Earnings Guidance for the Fiscal Year 2022